|
Stem and progenitor cells | Features and functions | References |
|
Hematopoietic stem or progenitor cells | |
Hematopoietic stem cells (HSCs) | Limited differentiation capacity compared to embryonic stem cells Commonly identified by the expression of CD34+ and CD133 cell surface antigens Clinically used for bone marrow transplantation in a variety of hematologic disorders Potentiality to differentiate into cardiac myocytes A subset of HSCs assume an endothelial phenotype promoting neovascularization by secreting proangiogenic growth factors and stimulating reendothelialization. These cells were named “endothelial progenitor cells” (EPC) The pattern of EPC surface markers includes CD133, VEGFR-2, CD34, Tie-1, Tie-2, CD146, c-Kit, and CXCR-4 | [13, 15, 16] |
H-myeloid cells | Mobilized from bone marrow CD14+/CD34+ myeloid cells coexpress endothelial markers, form tubelike structures ex vivo, and differentiate in endothelial cells incorporated in newly formed blood vessels Show a lower proliferation capacity than cord-blood-derived EPCs but have similar capacity to augment neovascularization in experimental models | [13, 15, 16] |
H-mesenchymal stem cells (MSCs) | Limited differentiation capacity compared to embryonic stem cells Located in bone marrow and adipose tissues Transdifferentiate into functional cardiomyocytes and a variety of other cells Modulate immune responses | [13, 15, 16] |
|
Nonhematopoietic stem and progenitors cells (non-HSCs) | |
Fat tissue | Can be obtained in large quantities under local anesthesia with minimal discomfort Adipose tissue-derived stromal vascular cells lack both CD31 and CD34 markers and differentiate into ECs promoting angiogenesis |
[13, 15–20] |
Liver and intestine | Progenitor cells derived from transplanted liver and intestine contribute to neovascularization after hind limb ischemia it is still debated whether these incorporated progenitors are derived from vessel wall in the organ or they are tissue-resident progenitor cells of nonvascular origin |
Spleen | Can differentiate to give an “EPC phenotype” and modulate endothelial function or vascular remodelling |
Kidney | Pax-2+ cells displaying mesenchymal markers CD133+ cells derived from human renal carcinoma are able to differentiate into ECs and were found to be directly incorporated into neovessels |
Skeletal myoblasts | First cells to be injected into the ischemic myocardium as part of a cell-based strategy Determine improvements in left ventricular function but little evidence shows transdifferentiation into cardiomyocytes |
Blood vessel wall | MSCs cells also called pericytes or adventitial cells |
|
Cord blood stem cells |
| Greater plasticity than adult cells due to their prenatal origin Lacking evidence of pluripotency after in vitro expansion Cord blood contains a number of progenitor cell populations, including HSCs and MSCs Having not yet been investigated in a clinical setting | [13, 15, 16] |
|